Thymogen

What Thymogen does

Thymogen is a two-amino-acid peptide used as an immune medicine in Russia. Its IM862 form did not beat placebo in cancer trials; older infection and recovery reports often lack dose or safety details. Small oral gel studies of thinning stomach lining often reuse participants. Long-term safety in healthy users remains unclear.

• A phase 3 trial of nasal IM862 in AIDS-related Kaposi sarcoma found no benefit; that failed cancer regimen does not establish a dose for immune support. (Studied in a trial)
• In Russia, doctors use it for patients with weak immunity during infection, wound or surgical care; this is not a US-approved use. (Studied in a trial)
• In a small blinded trial, people's wounds healed faster. (Studied in a trial)
• In studies of a gel taken by mouth for a thinning stomach lining, biopsy and inflammation markers improved; what that means for symptoms is unclear. (Studied in a trial)

Uses in the sources

• Russian medical use for immune deficits alongside infection, wound or surgical care. This is not an FDA/EMA indication. (Clinician-published) (source)
• Studied as an oral gel after H. pylori therapy for stomach-lining atrophy; tissue-marker findings need independent confirmation. (Studied in a trial) (source)
• Studied as IM862 for cancer. Controlled Kaposi and prostate trials did not establish benefit. (Studied in a trial) (source)
• Used in self-experiments aimed at immune aging; no controlled human lifespan benefit established. (Reported by users) (source)

Thymogen dosage

Typical reported dose: 5 mg twice a day, on 10 days each month

• Kaposi trial: 5 days on, 5 off: 5 mg nasal drops on each active dosing day 5 days on, then 5 days off; daily frequency unspecified, nasal spray. Studied in a trial. Studied in: Adults in the cited report. (source)
• Kaposi trial: alternate days: 5 mg intranasal every other day every other day, nasal spray. Studied in a trial. Studied in: Adults in the cited report. (source)
• Negative phase 3: alternate days: 5 mg intranasal every other day every other day, nasal spray. Studied in a trial. Studied in: Adults in the cited report. (source)
• Kidney trial: 20 mg three times daily: 20 mg intranasal three times daily three times daily, nasal spray. Studied in a trial. Studied in: Adults in the cited report. (source)
• Before surgery: 100 mcg daily: 100 mcg (0.1 mg) intranasal daily once daily, nasal spray. Studied in a trial. Studied in: Adults in the cited report. (source)
• Wound trial: 100 mcg daily: 100 mcg intramuscular once daily once daily, into muscle. Studied in a trial. Studied in: Adults in the cited report. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Thymogen

Comes as: Russian ready-made intramuscular solution: 100 mcg in a 1 mL ampoule, Russian metered nasal spray: 25 mcg per actuation, Russian 0.05% skin cream, Formulated powder for an oral gel, as studied in gastritis.

Mixed with: Injection solution already contains sodium chloride and water for injection. No added diluent is specified..

• A 1 mL injection ampoule contains 0.1 mg. It is not a multi-milligram freeze-dried research vial.
• No verified common community vial size, water volume or storage lifetime could be established.

Before mixing: Russian instructions: injection 0–10°C; historical nasal spray ≤25°C, dry and protected from light; cream 2–20°C. Check the exact formulation.

After mixing: Injection ampoules are ready-made; no validated home mixed-vial shelf life was found. Oral studies used freshly prepared gel.

Thymogen side effects and risks

Reported side effects

• Allergic reactions: Russian injection and nasal information gives no event rate., serious. Stop for a new allergic reaction; breathing trouble or throat swelling needs emergency care. (source)
• Headache with high nasal dosing: Grade 1 in 4/24 patients (16.7%, calculated) at 20 mg three times daily., mild. Discuss persistent or severe headache; these rates come from cancer patients. (source)
• Sinusitis: Two possibly related episodes among 24 assessed; one grade 1 and one grade 2., moderate. Seek review for persistent facial pain, fever or nasal discharge. (source)
• Ulcerative colitis flare: One possible drug related flare recurred on restarting in the 25 person kidney cancer study., serious. Stop and seek prompt care for bloody diarrhea or a clear bowel-disease flare. (source)
• Fatigue, tingling or nausea: Reported as mild/transient in the 44 person Kaposi phase 2 study; no counts., mild (source)
• Loose stools with oral gel: 2025 report: 2/9 in full text, 2/8 in abstract; resolved after 2 days., mild (source)
• Abdominal discomfort with oral gel: 1 patient reported discomfort during the first 5 days; small uncontrolled study., mild (source)
• Flu-like illness after nasal overdose: Historical Russian spray instructions describe this after ten times a single dose; no rate., moderate (source)

Stop and get help if

• Breathing trouble, throat swelling, widespread hives or faintness: Stop and call emergency services for possible severe allergy.
• Bloody diarrhea or severe worsening bowel pain: Stop and seek urgent care, especially with inflammatory bowel disease.
• Fever with a painful, hot or spreading-red injection site: Seek urgent care for possible infection from an injected product.

Who should avoid it

• pregnant: Human fetal safety is not established. Russian cream/spray instructions restrict pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; Russian cream/spray instructions restrict use.
• tryingToConceive: Precaution: reproductive safety and a preconception washout interval are not established.
• under18: Russian pediatric use does not establish safety of self-injected or unverified products.
• other: Russian instructions list hypersensitivity; cream ingredients can also cause allergy.
• activeCancer: Do not self-add during cancer care: IM862 lacked benefit and shortened progression time in one Kaposi trial.
• cancerHistory: No proven cancer-prevention benefit; review immune therapy with the cancer-care team.
• autoimmuneDisease: Immune stimulation may be unsuitable. A possible ulcerative colitis flare recurred after restarting IM862.
• immunosuppressed: Immune effects may oppose treatment goals; interactions with transplant drugs have not been established.
• other: A possible ulcerative colitis flare improved off drug and recurred on restarting.
• testedAthlete: No compound-specific anti-doping ruling verified; Russian approval complicates automatic S0 classification.
• kidneyDisease: Trials limited kidney impairment; clearance, dose adjustment and safety with kidney disease remain unknown.
• liverDisease: Trials limited major liver dysfunction; no validated dose adjustment exists for liver disease.
• other: Oral gel only (gastric-gel-trial): contraindicated during acute inflammatory disease of the stomach or duodenum.
• other: Oral gel only (gastric-gel-trial): sucrase/isomaltase deficiency is contraindicated. This restriction is not established for other formulations.
• other: Oral gel only (gastric-gel-trial): glucose-galactose malabsorption is contraindicated. This restriction is not established for other formulations.
• other: Oral gel only (gastric-gel-trial): the powder contains fructose; hereditary fructose intolerance is contraindicated.

Interactions

• High-dose systemic corticosteroids: Russian spray instructions say high doses can cancel its immune-stimulating action; clinical harm rates are unknown.
• Transplant and other immune-suppressing drugs: Theoretical opposing immune effects; no controlled Thymogen interaction study was found.
• Other thymic immune peptides: Community combinations exist; additive immune effects and combination safety are untested.

Product quality risks

• No Thymogen-specific independent survey of online product identity, amount, sterility or endotoxin was found.
• TGA’s peptide warning concerns poorly labeled imported vials with unverifiable contents; it is not a Thymogen contamination-rate study.
• The wrong linkage or amino-acid chirality can produce a different drug. Thymodepressin and golotimod are not interchangeable with Thymogen.
• A chemical purity percentage alone does not establish the amount per vial, absence of microbes, or absence of bacterial toxins.

What to expect

Controlled IM862 cancer trials found no clear benefit. The 59 human records include trial registrations, incomplete reports and stomach studies that reuse participants.

Key studies

• Kaposi sarcoma: two nasal schedules: Early responses were not confirmed in the later placebo-controlled trial. (source)
• Kaposi sarcoma: negative phase 3: IM862 did not beat placebo and may have accelerated progression. (source)
• Kidney cancer: no tumor responses: High nasal doses produced no objective cancer responses. (source)
• Prostate cancer: no clear benefit: IM862 did not prolong time to PSA progression. (source)
• Before abdominal cancer surgery: Fewer complications were reported, with important reporting errors. (source)
• Skin and soft-tissue wound trial: A small blinded trial reported faster wound healing. (source)

Thymogen FAQ

• Is Thymogen FDA-approved? No FDA-approved product or label identified. Foreign registration does not authorize US marketing or compounding.
• How do people take it? Under the skin, twice daily on days 1–10 of each month. 10 dosing days each month; no dose escalation reported. 9 months. Source: reported by users, not an established dose.
• What's the difference between Thymogen and Epitalon? Thymogen: a Russian peptide used for immune problems, with negative cancer trials. Epitalon: a peptide with telomerase effects in cells, but no proof that people live longer. Why people pair them: combined in thymus-aging and recovery self-experiments.
• Can I take it with Epitalon? Combined in thymus-aging and recovery self-experiments. One high-dose combination had worsening CT findings; causation is unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? It is unclear (WADA 2026). Not named in the 2026 list. S0 concerns substances without any governmental human approval; Thymogen has Russian registration. No specific ruling verified.
• How long does a mixed vial last? Injection ampoules are ready-made; no validated home mixed-vial shelf life was found. Oral studies used freshly prepared gel.